Sotera Health Q3 2024 Earnings Report
Key Takeaways
Sotera Health reported an 8.5% increase in net revenues, reaching $285 million for Q3 2024, compared to $263 million in Q3 2023. Net income was $17 million, or $0.06 per diluted share, a significant improvement from the net loss of $14 million, or $0.05 per diluted share, in the same quarter last year. The company reaffirmed its 2024 net revenue and Adjusted EBITDA outlook ranges.
Net revenues for Q3 2024 increased by 8.5% to $285 million compared to Q3 2023.
Net income for Q3 2024 was $17 million, or $0.06 per diluted share, compared to a net loss of $14 million, or $0.05 per diluted share in Q3 2023.
Adjusted EBITDA for Q3 2024 increased by 9.0% to $146 million compared to $134 million in Q3 2023.
Adjusted EPS for Q3 2024 increased to $0.17, up from $0.16 in Q3 2023.
Sotera Health
Sotera Health
Sotera Health Revenue by Segment
Forward Guidance
Sotera Health reaffirmed its 2024 outlook ranges, including net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%, Adjusted EPS in the range of $0.67 to $0.75, and a weighted-average fully diluted share count in the range of 283 million to 285 million shares. Capital expenditures are now expected to be in the range of $175 million to $185 million, from previous guidance of $205 million to $225 million.
Positive Outlook
- Net revenues growth in the range of 4.0% to 6.0%.
- Adjusted EBITDA growth in the range of 4.0% to 6.0%.
- Adjusted EPS in the range of $0.67 to $0.75.
- A weighted-average fully diluted share count in the range of 283 million to 285 million shares.
- Capital expenditures are now expected to be in the range of $175 million to $185 million, from previous guidance of $205 million to $225 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income